TCW Group Inc. Has $191.25 Million Holdings in Gilead Sciences, Inc. (GILD)
TCW Group Inc. raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 12.5% in the third quarter, HoldingsChannel.com reports. The firm owned 2,360,518 shares of the biopharmaceutical company’s stock after acquiring an additional 262,162 shares during the period. Gilead Sciences makes up 1.5% of TCW Group Inc.’s investment portfolio, making the stock its 16th largest position. TCW Group Inc.’s holdings in Gilead Sciences were worth $191,249,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also recently bought and sold shares of the company. Hanson & Doremus Investment Management lifted its stake in shares of Gilead Sciences by 806.5% in the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 1,613 shares during the period. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Gilead Sciences in the 2nd quarter worth approximately $147,000. Harel Insurance Investments & Financial Services Ltd. lifted its stake in shares of Gilead Sciences by 29.3% in the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 480 shares during the period. Rowland & Co. Investment Counsel ADV acquired a new stake in shares of Gilead Sciences in the 2nd quarter worth approximately $153,000. Finally, Capstone Investment Advisors Netherlands B.V. acquired a new stake in shares of Gilead Sciences in the 2nd quarter worth approximately $172,000. 75.94% of the stock is owned by hedge funds and other institutional investors.
In other news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $75.13, for a total transaction of $5,509,508.29. Following the sale, the insider now owns 3,070,099 shares in the company, valued at $230,656,537.87. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider John F. Milligan sold 220,000 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $72.88, for a total transaction of $16,033,600.00. The disclosure for this sale can be found here. Insiders have sold 461,666 shares of company stock worth $34,072,567 in the last 90 days. 1.30% of the stock is owned by company insiders.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $79.02 on Friday. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $86.27. The company has a market cap of $103,221.38, a P/E ratio of 9.00, a P/E/G ratio of -1.68 and a beta of 1.13. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating the consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. During the same period in the prior year, the business earned $2.75 earnings per share. The business’s quarterly revenue was down 13.2% on a year-over-year basis. equities analysts predict that Gilead Sciences, Inc. will post 8.53 EPS for the current year.
The company also recently declared a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 15th were issued a dividend of $0.52 per share. The ex-dividend date of this dividend was Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.63%. Gilead Sciences’s dividend payout ratio is currently 23.69%.
GILD has been the subject of a number of research analyst reports. Berenberg Bank set a $96.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Thursday, October 19th. Mizuho reaffirmed a “buy” rating on shares of Gilead Sciences in a research note on Friday, September 29th. William Blair reaffirmed a “buy” rating on shares of Gilead Sciences in a research note on Thursday, October 19th. JPMorgan Chase & Co. set a $85.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Finally, Maxim Group raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and upped their price target for the stock from $73.67 to $94.00 in a research note on Thursday, November 30th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $85.03.
COPYRIGHT VIOLATION NOTICE: “TCW Group Inc. Has $191.25 Million Holdings in Gilead Sciences, Inc. (GILD)” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2018/01/14/tcw-group-inc-has-191-25-million-holdings-in-gilead-sciences-inc-gild.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.